Обзор американских кардиологических журналов за неделю (ссылки)

[Chevychelov]

Extended-Release Niacin or Ezetimibe and Carotid Intima-Media Thickness
Taylor AJ, Villines TC, Stanek EJ, et al.
N Engl J Med 2009;Nov 15:[Epub ahead of print].
Study Question: What is the effect of niacin or ezetimibe on common carotid intima-media thickness (CIMT) when added to statin therapy?
[Ссылки доступны только зарегистрированным пользователям ]

Cardiovascular and Noncardiovascular Mortality Among Patients Starting Dialysis
de Jager DJ, Grootendorst DC, Jager KJ, et al.
JAMA 2009;302:1782-1789.
Study Question: Cardiovascular (CV) mortality is considered the main cause of death in patients receiving dialysis and is 10 to 20 times higher in such patients than in the general population. Is the high overall mortality in patients with end-stage renal disease (ESRD) starting dialysis a consequence of increased CV mortality risk only, or is non-CV mortality equally increased?
[Ссылки доступны только зарегистрированным пользователям ]

Ferric Carboxymaltose in Patients With Heart Failure and Iron Deficiency
Anker SD, Colet JC, Filippatos G, et al., on behalf of the FAIR-HF Trial Investigators.
N Engl J Med 2009;Nov 17:[Epub ahead of print].
Study Question: Does treatment with intravenous iron (ferric carboxymaltose) improve symptoms in systolic HF and iron deficiency, either with or without anemia?
[Ссылки доступны только зарегистрированным пользователям ]

Effects of High-Dose Versus Low-Dose Losartan on Clinical Outcomes in Patients With Heart Failure (HEAAL Study): A Randomized, Double-Blind Trial
Konstam MA, Neaton JD, Dickstein K, et al.
Lancet 2009;374:1840-8.
Study Question: How does high-dose losartan (an angiotensin-receptor blocker [ARB]) compare versus low-dose losartan on clinical outcomes in patients with heart failure (HF)?
[Ссылки доступны только зарегистрированным пользователям ]

Advanced Heart Failure Treated With Continuous-Flow Left Ventricular Assist Device
Slaughter MS, Rogers JG, Milano CA, et al., on behalf of the HeartMate II Investigators.
N Engl J Med 2009;Nov 17:[Epub ahead of print].
Study Question: How does the newer HeartMate II left ventricular assist device (LVAD; a continuous-flow device) compare with the older more durable HeartMate XVE (a pulsatile-flow device)?
[Ссылки доступны только зарегистрированным пользователям ]

Platelet Inhibition With Cangrelor in Patients Undergoing PCI
Harrington RA, Stone GW, McNulty S, et al., on behalf of CHAMPION PCI Investigators.
N Engl J Med 2009;Nov 15:[Epub ahead of print].
Study Question: What is the benefit of cangrelor, a reversible adenosine diphosphate (ADP) receptor antagonist, in patients undergoing percutaneous coronary intervention (PCI)?
[Ссылки доступны только зарегистрированным пользователям ]

Intravenous Platelet Blockade With Cangrelor During PCI
Bhatt DL, Lincoff AM, Gibson CM, et al., on behalf of the CHAMPION PLATFORM Investigators.
N Engl J Med 2009;Nov 15:[Epub ahead of print].
Study Question: What is the benefit of cangrelor, a reversible adenosine diphosphate (ADP) receptor antagonist, in patients undergoing percutaneous coronary intervention (PCI)?
[Ссылки доступны только зарегистрированным пользователям ]

Absolute Myocardial Blood Flow Determination Using Real-Time Myocardial Contrast Echocardiography During Adenosine Stress: Comparison With Single-Photon Emission Computed Tomography
Abdelmoneim SS, Dhoble A, Bernier M, et al.
Heart 2009;95:1662-1668.
Study Question: What is the feasibility and accuracy of real-time myocardial contrast echocardiography (MCE) to detect myocardial perfusion abnormalities using simultaneous technetium 99 m sestamibi single-photon emission computed tomography (SPECT) as a standard?
[Ссылки доступны только зарегистрированным пользователям ]

A Selective Endothelin-Receptor Antagonist to Reduce Blood Pressure in Patients With Treatment-Resistant Hypertension: A Randomised, Double-Blind, Placebo-Controlled Trial
Weber MA, Black H, Bakris G, et al.
Lancet 2009;374:1423-1431.
Study Question: What is the blood pressure-lowering effect of the new vasodilatory, selective endothelin type A antagonist, darusentan, in patients with treatment-resistant hypertension?
[Ссылки доступны только зарегистрированным пользователям ]